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Introduction
Dilated cardiomyopathy (DCM) is still a leading cause 
of cardiac death in children (1,2). DCM of the left 
ventricle (LV-DCM) is characterized by LV-ejection 
fraction (LV-EF) of less than 40% and LV-end-diastolic 
dimension (LVEDD) with z-values above +2; LVEDD 
with a z-value of above +5 has a low incidence of 
spontaneous recovering may be maximal of 10–15% of the 
patients (2). Idiopathic and myocarditis related LV-DCM is 
the domain in infants and young children, while in adult’s 
systolic cardiac dysfunction and dilatation is preferentially 
based on an ischemic myocardial disease (3). Considering 
the “traditional” pediatric CHF-therapy as symptom- 
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oriented and non-curative (4,5), report from the working 
group of the National Institutes of Health reminds major 
new initiatives for the development of new therapies in 
children with heart failure (6). Patients with “end-stage” 
heart failure and maximal guideline-related medical therapy 
are listed for heart transplantation (HTx), in some also 
bridged by an assist device. HTx is considered as the only 
viable life-saving option despite its palliative character 
with reduced long-term survival (7,8); further, limited by 
donor availability, its costs and life-long immunosuppressive 
treatment with its negative consequences in long-term. 
From global health perspective, HTx is available to only a 
very small minority of affected children; therefore, there 
is a pressing need for alternative therapies. Regarding the 
enormous potentials for cardiac regenerative, reciprocal to 
the patient’s age, alternatives are obvious and should took 
into account [Michel-Behnke et al. (9)]. In this context, 
it has to be considered that left and right ventricle do 
not act in isolation; they are inextricably linked through 
a common septum, shared myofibers and pericardial 
space (10); LV contraction contributes more than 50% 
of RV work (11). Despite of novel experimental and 
clinical observations (12-15), the potential’s of ventricular-
ventricular (V-V) interactions in either LV or RV failure 
has not been harnessed for therapeutic benefit. Here, 
we hypothesize that V-V interactions have enormous 
therapeutic potential in patients with LV-DCM. Therefore, 
we introduced reversible pulmonary artery banding (rPAB) 
to the therapeutic arsenal in left heart failure with reduced 
ejection fraction (HFrEF), but preserved RV-function; it 
seems to constitute a paradigm shift, particularly for infants 
and children with end-stage DCM (16-18). Reversible PAB 
is a promising therapeutic option with the potential to be a 
clinical ‘game changer’ (19).
PAB in LV-DCM, why?
The aim of surgical performed PAB is to support functional 
recovery of LV-DCM. 
It is hypothesized, that rPAB shifts the interventricular 
septum back to the left by forcing a pathological, round, 
“apple-like” left ventricular shape to its normal, ellipsoid 
“pear-like” morphology (20,21); aiming that the function 
follows the morphology. Thereby, PAB induced RV stress 
improves LV filling dynamics as well as end-diastolic 
volume and pressure via Anrep and Frank-Starling effects 
(Figure 1A,B) .  Together with restored ventricular 
electromechanical synchrony, increased LV ejection fraction 
and less left atrial congestion, PAB becomes responsible 
for clinical improvement at rest and during exercise (21). 
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PAB-effects on right (RV) and left (LV) ventricle
Figure 1 Summarizes the pulmonary artery banding (PAB) effects on the right (RV) and left ventricle (LV). (A) Depicts the magnet 
resonance imaging (MRI) in four-chamber view of an infant with left ventricular dilated cardiomyopathy (LV-DCM); (B) shows functional 
regeneration of the LV based on the PAB induced ventriculo-ventricular interaction (VVI); the MRI was performed before the PAB induced 
RV hypertension was unloaded by transcatheter balloon dilation. IVS, interventricular septum; LA, left atrium; MV, mitral valve; TV, 
tricuspid valve.
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Initially, the idea was born by observing the favourable 
results of PAB in patients with congenital corrected 
transposition of the great arteries (ccTGA), in which long-
term outcome is directly related to a balanced VVI and the 
competence of atrio-ventricular valve (22,23). Pathological 
enlargement of a sub-aortic positioned systemic RV is 
significantly longer be prevented by a pulmonary or 
left ventricular out-flow tract obstruction, but even by 
pulmonary artery hypertension. Surgical PAB is used in case 
of an unloaded sub-pulmonary positioned LV and thereby 
missing counter bearing effect avoiding RV dilatation (23). 
PAB is used for retraining a sub-pulmonary LV, but even as 
a preventive strategy for neonates born with ccTGA without 
congenital pulmonary or sub-pulmonary obstruction (24). 
Entry- and exclusion-criteria were developed for young 
children with LV-DCM and preserved right ventricular 
function (Table 1); aiming functional recovery, instead HTX 
or death (17). The efficacy of a placed PAB seems to be 
reciprocal to the patient’s age because of the endogenous 
potential’s of myocardiocyte recovery and repopulation 
(25-27). Animal models with distinction of age have shown 
that chronic PAB increases myocytal size during RV-
hypertrophy accompanied by cell growth directed gene 
expression pattern together with a parallel augmented 
capillary network (28,29). Additionally, risk-benefit of 
surgical PAB seems even be reciprocal to the age particularly 
in severely diseased patients with LV-DCM. Additionally, 
young infants have the chance to grow-in the PAB; thereby 
the RV can smoothly adapt to a systemic pressure level and 
the LV becomes a high chance for functional recovery (18). 
PAB in LV-DCM, how?
Before a reversible PAB is considered treating a LV-DCM, 
the diagnosis DCM must be secured. The difference 
between DCM and a dilated LV caused by pressure (aortic 
coarctation, critical aortic stenosis) or volume overload 
(MV regurgitation) can oftentimes be made by the LV 
contraction behavior in term of a-synchronic versus 
synchronic contraction profile. Completed diagnostic work-
up is mandatory; especially in a young infancy! Clinical and 
imaging examination have to exclude causative structural 
heart defects as an aortic coarctation or critical aortic 
stenosis; MRT imaging can additionally figure out RV 
function and form (RV-EF) in context of the diseased LV 
(LV-non compaction criteria, myocarditis; ischemic areas 
late enhancement? etc.). The determinants of cardiac output 
needs to be in account; beyond heart rate, contractility 
preload and afterload, parameters of ventriculo-ventricular 
interaction, interatrial and atrial-ventricular as well as 
ventriculo-arterial coupling have to be analyzed.
Heart catheterization need to be additionally performed 
for excluding coronary anomalies, obstructions, fistulae 
etc.). Myocardial biopsies or therapeutical issues as creating 
a restrictive ASD should further be considered as ever 
possible. 
Placing a surgical band around the pulmonary artery 
trunk is technically simple, the band has to be performed 
that neither the pulmonary valve nor the bifurcation of 
pulmonary artery is bothered. Therefore, the band should 
be additionally fixed at the adventitia of the PA avoiding 
distal migration. PAB has a low risk in patients with 
ventricular septum defect to reduce a left-right shunt. 
Restriction of pulmonary artery blood flow balancing 
systemic-pulmonary circulations is mostly associated with 
normal or hyper-dynamic ventricular function. In case of 
Table 1 Inclusion and exclusion criteria for PAB 
Inclusion criteria
Age 0–6 years
Left-sided ventricular dilated cardiomyopathy with preserved 
right ventricular function (EF >45%)
Left ventricular end-diastolic diameter (LVEDD) Z-score >+4.5
Ejection fraction (EF) <30% despite inotropic & anti-congestive 
therapy
Acceptable candidate for mechanical circulatory support and/
or heart transplantation (HTx)
Clinical functional status III–IV (hospitalized)
Parental consent
Exclusion criteria
Age greater than 5 [12] years
No parental consent
Biventricular end-stage DCM
Acute/per-acute myocarditis
Concomitant structural (congenital) heart disease, with the 
exception of repaired ALCAPA
Moderate-severe tricuspid valve regurgitation
Pulmonary hypertension out of proportion with left-ventricular 
end-stage cardiomyopathy
Hereditary disease associated with bi-ventricular dysfunction
DCM, dilated cardiomyopathy; PAB, pulmonary artery banding.
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LV-DCM, the PAB approach however needs to be carefully 
prepared, performed and followed initially by a continuous 
hemodynamic control. 
The pediatric cardiac surgeon, anesthesiologist, 
intensivist and cardiologist have to have the common 
sense, that the child should become the chance for cardiac 
recovering instead HTx. It needs this one focus, if one 
member of the team is disagreeing, the open-chest method 
of PAB should not be performed in young children with 
“end-stage” LV-DCM. One physician, best the pediatric 
cardiologist familiar with the pathophysiology and peri-
operative as well as long-term heart failure therapy should 
take close care for the patient; coordinating the procedure, 
which also includes timing of the surgical approach and 
involving closely the parents in any step of this novel 
treatment for cardiac recovery. 
The summarized methods according our protocol
According the entry & exclusion criteria (Table 1), PAB is 
currently offered to young children {<6 [12] years} with 
LV-DCM and preserved RV-EF admitted for HTx or 
HTx evaluation; the parents have given written informed 
consent; the history and the treatment at admission is 
documented, but immediately adapted to the protocol 
specifications (Tables 2,3), which also respects the receptor-
specific differences between DCM in children and adults 
(30,31). Therefore, all infants and children undergoing a 
rPAB are being treated with a β1-specific beta-blocker (B, 
Bisoprolol), a tissue ACE-inhibitor (L, Lisinopril) and a 
mineralocorticoid-blocker (S, Spironolactone), while we 
avoid diuretics to the extent it is possible (32,33). Avoiding 
intra-vascular volume deficit with a risk for hypotension 
during the establishment of B-L-S or even continuous 
milrinone infusion, all loop-diuretics have to be stopped 
as a minimum of 12–24 before this specific treatment is 
started. Aiming, that surgical PAB needs to be paired with 
an improved anti-congestive therapy favoring cardiac 
functional recovery (34). Inhibition of endogenous neuro-
humoral activation is only one significant part of cardiac 
treatment, but protecting cardiomyocytes and cardiac 
interstitium is a further strategy reducing mechanical stress 
Table 2 Medical therapy (cardiac anti-congestive/anti-remodeling therapy)
Drugs Dosages Comment 
Bisoprolol (B) 0.05–0.1–0.2 (0.3) mg/kg/d Adaption to SAP/HR (avoid diuretics)
Lisinopril (L) 0.05–0.1–0.2 (0.3) mg/kg/d Adaption to SAP/fluid status!
Spironolactone (S) 1–[2] mg/kg/ED Anti-remodeling dosage!
Digoxin Saturation dosage 0.01 mg/kg/8 h HR-control together with (B)
Daily dosage: 0.008 mg/kg/d (blood level: 
0.5–0.8 nmol/L)
Furosemide 0.5 mg/kg ED if necessary Not for chronic therapy
Hydrochlorothiazide 1–[2] mg/kg ED If possible, avoid diuretics (D)
HR, heart rate.
Table 3 Supplemental therapy (cardiac anti-congestive/anti-remodeling therapy)
Drugs Dosage Goals
Co-Enzyme Q 10–15 mg/kg/d All DCM-patients
Riboflavin 3–20/mg/d Mitochondriopathy
Carnitin 25–100 mg/kg/d If deficient
Nicotinamid 50 mg/kg/d Mitochondriopathy
Erythropoietin 150 U/kg/3×/wk Goal: Hb 12–14 g/dL
DCM, dilated cardiomyopathy.
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related fibrosis of the RV by PAB (29,35). Clearly, long-
term risks and benefits need to be analyzed in a multicenter 
study, but all current retrospective data supports the here-
recommended “modus operandi”.
Assuming the diagnosis “LV-DCM with preserved RV-
EF” made by history—age for example 6 months—clinical 
examination, ECHO, cardiac MRI-imaging as shown in 
Figure 1A; then assessing normal LA-size, there is obviously 
no indication for diuretic treatment, as seen in the majority 
of young patients admitted even for HTx evaluation; in 
case of an increased heart rate of >140/min with or without 
concomitant therapy by catecholamines, as it is also usually 
performed, diuretics need to be stopped, feeding allowed ad 
libitum, before B. and L. is started with an orally dosage of 
0.1 mg/kg each and S. of 0.5–1 mg/kg; all drugs need only 
applicated once per day. Aiming a heart rate of less than 
110/min at rest (sleep) even in young infancy together with 
a normal breath rate and sufficient systolic and diastolic 
blood pressure. Sometimes, catecholamines, in particular 
continuous infusion of epinephrine, can only be stopped 
and might be changed to milrinone, if a volume challenge 
is performed by a short infusion (10–20 mL/kg) of 
Ringer® solution and/or by increasing Hb to 12–14 g% by 
transfusion of red cell package; both, by careful monitoring 
the blood pressure, which have to remain stable or increase 
but not decrease. Cardiac catheterization is followed with 
coronarography (ALCAPA-exclusion) and myocardial 
biopsies; myocardial biopsies will be obtained for routine 
histopathological analysis and viral persistence. Creation of 
a restrictive atrial septum defect is indicated, when diuretics 
are really needed treating pulmonary congestion; imaging 
as well as LA-pressure or PCWP-measuring evidenced the 
indication creating a restrictive atrial septum defect (36,37).
Counseling worldwide physicians with the question “is our 
patient a candidate for PAB?” our answer is usually as following: 
please sent history, age, current treatment, echocardiographic 
data as movies of the four-chamber, long- and short-axis view; 
LVEDD z-score as well as LV- and RV-EF, obtained best 
by MRI, if available.
PAB-procedure briefing step-by-step (based on a usually 
referred infant-patient)
Prior to surgical PAB appropriate interval during follow-
up surveillance is allowed to prepare “listing” for HTx 
and establishing perioperative medical therapy. Already 
established, long-acting bisoprolol is applicated about 6 
to 12 hours before surgery for reversible PAB is provided; 
continuous intravenous infusion of milrinone is usually 
established together with B-L-S days before in a dosage, 
adapted to 1 µg/kg × min. Twelve hours before surgical 
PAB, levosimendan has additionally be infused in a dosage 
of 0.1 µg/kg × min without loading dose; the infusion 
should be continued for further 12 hours during anesthesia 
for PAB surgery and on PICU. Reversible PAB is also 
being applied even in lieu of mechanical circulatory support 
(left-heart assist device) or for weaning of already existing 
extracorporeal mechanical oxygen (ECMO). 
Open chest surgery is performed under continuous 
monitoring of heart rate (HR), systemic atrial blood 
pressure (SAP), right atrial pressure (RAP), pulse oximetric 
oxygen saturation and cerebral near infrared spectroscopy 
(cNIRS) calibrated to oxygen saturation obtained from 
the upper caval vein. Anesthesia is mostly performed by 
midazolam, fentanyl, vecuronium in a continuous infusion 
and small single dosages, if needed; additionally, continuous 
infusion of clonidine (1–2 mg/kg/hour) is established or 
continued; infusion of epinephrine (0.01–0.05 µg/kg/min) 
and norepinephrine (0.01–0.2 µg/kg/min) are prepared to 
start several minutes prior to PAB-application, if not already 
applicated for treatment of cardiac failure before. 
A sternotomy and partial pericardia incision is used placing 
the rPAB. It has to be aware, that the V-V-I is immediately 
changed, when the pericardium is opened (blood pressure 
decrease, heart rate increase!). Therefore, the surgical 
approach should be well prepared (volume, Hb!) and shortened 
as possible; the pericardium needs to be carefully closed 
at the end of the procedure, again by close hemodynamic 
monitoring. A polyethylene 21G (arterial) cannula is placed 
within the right ventricle by transmural puncture, and fixed 
by a purse-string suture (Figure 2). The band has to be 
placed carefully around the pulmonary arterial trunk without 
compromising the systemic and in particular coronary blood 
flow; before the PAB is tightens, hemodynamic and oxygen 
transport parameters have to be stable:
 Heart rate (HR, influenced by long-acting bisoprolol, 
and clonidine infusion) should be less than 145/min, 
preferred <125/min despite catecholamine support;
 Right atrial pressure (RAP) need to be above 
5 mmHg (sufficient intravascular volume and 
hemoglobin >12 g%), but less than 12 mmHg;
 Systolic arterial pressure (SAP)—age- and anesthesia-
dependent—should be above 70–[80] mmHg, if the 
RVP is less than 35 mmHg; 
 Arterial-venous oxygen saturation difference (Sa-
vDO2) should be <40%, preferred <30%;
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 TAPSE (tricuspid annular plane systolic excursion), 
degree of the mitral valve regurgitation (MR) as 
well as the interventricular septal position (IVS) are 
additionally monitored by TEE, all TEE- parameters 
should analyzed before, during, after PAB; 
 LAP-RAP gradient should also be determinated 
by TEE, in case of persistent foramen ovale or 
percutaneous created restrictive ASD.
Tightening of the already under the PA placed band 
(PTFE or Dacron) should be performed smoothly under 
continuous hemodynamic monitoring and TEE control 
until the IVS becomes slightly shifted leftwards. Usually, 
the PA-circumference can be reduced to about 50–60% 
of the diameter of the pulmonary valve annulus without 
jeopardizing SAP or an increasing RAP above 10 mmHg; 
depending on the PAB-induced decrease of TAPSE, a 
systolic RVP/SAP ratio of 0.6 might be achieved; the 
pressure gradient across the PAB immediately after band 
placement is usually “only” 20–25 [35] mmHg; the true 
pressure gradient can be measured, when the RV-function 
is re-adapted (TAPSE back to basic value), mostly seen just 
before the patient is discharged home. Considering the 
reversibility of the PA-band, two sutures with prolene 6.0 
(5.0) are used allowing the chance for partial or complete 
de-banding by transcatheter balloon dilatation; a further 
prolene suture is placed 3–5 mm above the first double 
suture-line giving the chance not only for patient’s grown-
in the PAB, but even to establish a live-long residual band-
effect, which might be necessary and we favor in LV-DCM 
associated with a non-compaction morphology. 
During open chest PAB approach, myocardial function 
is augmented with catecholamines and inodilators (see 
above); once the postoperative hemodynamics are instable 
in particular when systemic hypotension is induced by 
patient’s agitation, the patient needs be muscle relaxed 
until stability is established. However, usually the patient 
is extubated early after surgery and cardiac protecting 
drugs B-L-S are early re-established, even still during 
continuous catecholamine support (Tables 2,3; Figure 3). 
The highly specific β-1-adrenoreceptor blocker bisoprolol 
or the intravenous variant metoprolol or esmolol should 
already protect against the endogenous and exogenous 
β1-adrenergic stimulation with deleterious cardiac effects 
(myocyte apoptosis, necrosis); β2-receptors with its quite 
different receptor-related pathway should however be 
preserved considering its cardiac protective, hypertrophy 
supporting and stem cell mobilizing effects (31); possible 
(β2-R) side effect, if additionally stimulated by continuous 
β2-agonists in particular its chronotrope action can 
sufficiently be blocked by sufficient β1-receptor blockers 
combined with the anti-tachycardia effects of clonidine; in 
some patients digoxin or even ivabradin (0.1 mg/kg) are 
additionally used. As mentioned above, catecholamines have 
to wean off gradually over a short period of days (TAPSE!!), 
when milrinone is still continuously infused; milrinone is 
weaned over 1–2 (–4) weeks most by deceasing the dosage 
of 0.1 µg/kg × min per day by monitoring the clinical 
condition (Ross-status, and BNP-values). The infants are 
separated from mechanical ventilation within the first 
post-rPAB day(s) or seldom week(s), and enteric feeding is 
resumed immediately given all recommended oral drugs 
back in a sufficient dosage (Table 2). The infant is discharged 
on oral medications (B-L-S) by avoiding furosemide, 
but in some by low-dosage of hydrochlorothiazide 
(0.5–1 mg/kg) in 1 or 2 oral applications per day; 
supplemental drugs are applicated long-term (Table 3); 
erythropoietin, which is administered 3×/weeks in a 
dosage of 100–150 IE/kg iv/im as long as the patient is 
not discharged home. Every child is kept under frequent 
clinical surveillance. The infants’ short- and long-term 
surveillance will include parent’s education to monitor/
observe the breath rate at sleep and by taught parents 
applicate safely the oral drugs, in particular the three 
most important one B-L-S once per day; the parental 
compliance effect is usually excellent. Intermittent clinical 
examinations in close contact to the Pediatric Heart C enter 
have not only monitored height, weight, electrocardiogram, 
Trans-ventricular cannulation measuring RV-pressure during PAB
Figure 2 Shows the open chest and pericardial approach for 
performing pulmonary artery banding (PAB); the PAB is already 
placed, the 21 gauge (arterial) cannula is still in place measuring 
the RV pressure before and after PAB placement. 
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echocardiogram, cardiac MRI, plasma BNP levels, but even 
the parent’s reported history; the indication for an invasive 
examination is ordered by the responsible Heart Center, in 
particular heart catheterization for re-myocardial biopsies 
or PAB de-banding by PAB-ballooning.
PAB in LV-DCM; how long?
The first rPAB approach to treat LV-DCM was performed 
meanwhile 12 years ago, when the patient was listed as 
a newborn for HTX over 2 months without a realistic 
chance receiving a donor heart (16). Meanwhile, he is de-
banded since years by transcatheter technique and still 
living with a NYHA functional class I without limited 
cardiac function despite minimal morphological changes 
in term of signs of bi-ventricular hypertrophy. Considering 
the last update, published as worldwide retrospective data 
analysis (18), it can be assumed, that more than 100 infants 
A
B
Figure 3 Distinctive perioperative treatment. 
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and young children have currently undergone rPAB 
with end-stage DCM for bridging to HTx or functional 
recovery. To best of our knowledge, PAB-procedure related 
mortality is not described until now. PAB-responder, 
remarkable clinical and morphological improvements of 
the LV cardiac function with a reverse remodeling in term 
of normalization of LV-size, LV-ejection fraction, and 
mitral valve regurgitation is usually observed between 3 to 
9 months after PAB-placement (Figure 1B). The majority of 
patients could be de-listed from transplant list. Following 
further improvement in their clinical and hemodynamic 
status, complete or partial de-banding of the pulmonary 
artery can be performed by transcatheter technique utilizing 
a gradual balloon dilatation by utilizing high-pressure 
balloons. Based on our first, negative experience in DCM-
patients associated with a non-compaction LV morphology 
(17,18), in who complete transcatheter de-banding led to 
cardiac decompensation despite a fantastic initial response 
on PAB with normalizing LV form and function, we 
decided against complete RV-unloading. Since these initial 
experiences, we led a residual RV hypertension of 50–60% 
of the systemic level in all patients with non-compaction 
morphology, even when the LV recovered fully during 
the follow-up. Complete or even partial transcatheter de-
banding can be easily performed, if the above described 
surgical PAB-technique is used. The indication for PAB-
debanding is made, when clinical signs of exercise-
intolerance becomes obvious despite a well functional LV. 
Usually, RV-distress with ventricular dilatation and high 
pressure gradient across PAB is usually observed together 
with a moderate tricuspid valve regurgitation and secondary 
increase of plasma B-type natriuretic peptide (BNP). Band 
enlargement may be accomplished in stages, ultimately 
opting for a mild residual right ventricle-main pulmonary 
artery pressure gradient of 15–30 mmHg. As mentioned 
above, he technique of PAB-ballooning depends on the 
annulus of the pulmonary valve; we don’t use balloons with 
a diameter above the PA-valve annulus; we starting with a 
high-pressure balloon with diameter of about 50% larger 
than the smallest measured PAB-diameter (for example 
4–5 mm PAB vs. 8 mm balloon diameter); followed by a 
bigger balloon, when re-angiography and pressure gradient 
measurement are performed again and in consideration of 
the final aim to achieve a partial of complete PA-debanding.
PAB in LV-DCM: preliminary conclusion
Usually, left and right heart failure is considered separately, 
but from the pathophysiological point of view, both, right 
and left heart function is inextricably linked through a 
common septum, shared myofibers and pericardium. 
Application of a reversible PAB utilizes great potentials 
of VVI to treat LV failure with reduced ejection fraction 
(HFrEF). First ‘proof-of-principle’ results imply that 
rPAB in LV failure provides a novel alternative ‘bridge-to-
transplant’ or destination therapy in infants and children 
with advanced LV-DCM. Technically, rPAB is simple, safe, 
effective and affordable making it a realistic option for 
children worldwide, especially where transplant is not an 
option. In young infants with the potentials of regeneration; 
with the option to grown-in the PAB, the surgical PAB 
can be performed with very low risk, but highly effective; 
there is no need for a tight PAB, as it was shown even 
in ccTGA patients in whom a banding is considered in 
young infancy as prophylactic tool. Independent of the 
patient’s age, a provided PAB procedure needs to be 
performed as standardized measure independent if the 
perioperative strategy is considered as low- or high-risk 
approach. In any case, pathophysiological aspects and the 
current pharmacological knowledge of a patient designed 
pediatric heart failure therapy have to be taken in account. 
Currently, we have demonstrated therapeutic benefit only 
in infants and young children whose myocardium may have 
high potential for regeneration; however, the pediatric 
DCM population in total has not been clearly defined who 
may benefit from this novel V-V-interactive procedure. 
The need for a prospective, randomized study is obvious 
to evidence rPAB in LV-DCM; clinical outcomes with 
biochemical profiling are warranted as well as the impact 
of PAB to diminish the need for mechanical circulatory 
support and cardiac transplantation.
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